Eribulin Yields Similar Benefit to Standard Chemotherapeutics for HER2-low and HER2-0 Metastatic Breast Cancer
December 08, 2022

Patients with HER2-low or HER2-0 metastatic breast cancer who previously received at least 1 chemotherapy agent garnered similar benefit from eribulin mesylate vs standard physician's choice chemotherapies.

Capivasertib Plus Fulvestrant Yields PFS Improvement in HR+/HER2– Breast Cancer
December 08, 2022

Results from the phase 3 CAPItello-291 trial indicated that the combination of capivasertib plus fulvestrant produced improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.

Bispecifics in Development for the Treatment of R/R MM
December 08, 2022

Dr Tuchman highlights exciting bispecific agents in investigation for the treatment of relapsed/refractory multiple myeloma.

Trastuzumab Deruxtecan Maintenance after First-Line Therapy for HER2+ mBC
December 08, 2022

Joyce O’Shaughnessy, MD, starts a discussion on maintenance therapy with trastuzumab deruxtecan in patient with HER2+ mBC.

Practical Factors in Selecting Therapy for Relapsed/Refractory MM
December 08, 2022

Shared insight on key factors that determine the best selection of therapy in patients with relapsed/refractory multiple myeloma, with a focus on bispecific antibodies and CAR T-cell therapy.

Patient Case 3: A 65-Year-Old Woman With Relapsed Multiple Myeloma
December 08, 2022

After reviewing their third patient case, expert hematologist-oncologists highlight the treatment armamentarium for relapsed/refractory multiple myeloma.

Treatment Options for Patients with Relapsed Multiple Myeloma
December 08, 2022

Peter Voorhees, MD, starts a conversation on the best treatment options for patients with multiple myeloma after relapse.

Case Presentation: A 69-Year-Old Woman with HER2+ Metastatic Breast Cancer (mBC)
December 08, 2022

Heather McArthur, MD, presents the case of a 69-year-old woman with stage II HER2+ mBC for discussion.

Neoadjuvant Trastuzumab Deruxtecan ± Endocrine Therapy Demonstrates Promise in HR+ HER2-Low Breast Cancer
December 08, 2022

Data from the phase 2 TRIO-US B-12 TALENT trial indicate that fam-trastuzumab deruxtecan-nkxi in the neoadjuvant setting with or without endocrine therapy could be beneficial for patients with hormone receptor–positive, HER2-low breast cancer.

Yoga May Improve DFS, OS in Patients with Non-Metastatic Breast Cancer
December 07, 2022

Yoga and conventional exercises also demonstrated long-term improvement in quality of life during treatment for non-metastatic breast cancer, according to results presented at the 2022 San Antonio Breast Cancer Symposium.